Antibody Discovery
Brochure: Antibody Discovery
Find out how Opto™ Plasma B Discovery using the Beacon® optofluidic system accelerates lead molecule discovery against difficult targets.
App Note: Discover Lead Molecules Against Difficult Targets Inaccessible by Hybridoma Methods
Download this application note to learn about how the Opto™ Plasma B Discovery workflow increases hit recovery for difficult membrane-bound targets and provides access to greater sequence diversity when compared to traditional hybridoma methods.
Datasheet: Opto™ Plasma B Discovery 4.0
Review workflow overview and representative results.
Product Tour: The Opto™ Plasma B Discovery 4.0 Workflow
Antibody expert, Anupam Singhal, PhD, does a 10-minute walkthrough of how the Opto™ Plasma B Discover workflow makes it possible to accelerate lead molecule discovery against difficult targets.
Webinar: Tackle Difficult Targets by Accessing Broad B Cell Diversity
Watch our presentation at AE&T Digital Week, hosted with Genovac, to hear how the Beacon system is making it possible to find 10 times more lead candidates than hybridoma in just days.
Webinar: A Beacon for Rapid Antibody Discovery against Difficult Targets
Panelists from Genovac, will present case studies of how they have leveraged their core genetic immunization technology and the Beacon optofluidic system to rapidly discover antibodies against challenging targets, such as GPCRs, from a variety of different animal species.
Application Note: Rapid High-Resolution Screening of Plasma B Cells to Identify Antibody Lead Candidates
Explore case studies for the rapid discovery of antibodies against challenging targets.
Customer Spotlight: Abveris on Antibody Discovery
Find out how Abveris is transforming their antibody discovery processes with the Beacon® optofluidic system.
Customer Spotlight: Amgen on AbD and CLD
Find out how Amgen is transforming their antibody discovery and clonal cell line processes with the Berkeley Lights Platform.
Application Note: Rapid Discovery of Therapeutic Antibodies for the SARS-CoV-2 Pandemic Virus Using the Opto Viral Neutralization 1.0 Workflow
Learn how to use blocking and binding assays and the Opto Viral Neutralization 1.0 workflow to identify cross-reactive antibodies that may have broad neutralization capacity across the coronavirus family.
Webinar: Rapid Discovery of a Diverse Panel of Antibodies Against Membrane Targets Using the Beacon System
Dr. Shireen Khan presents a case study on how ChemPartner has leveraged the Beacon system to rapidly discover cross-reactive antibodies against the GPI-anchored uPA receptor.
Webinar: Rapid Discovery of Functional Antibodies for SARS-CoV-2 Using the Beacon System
Robert Carnahan, PhD, and Seth Zost, PhD, from the Vanderbilt University Medical Center, describe how they have used the Beacon platform, to rapidly discover hundreds of unique antibodies against SARS-CoV-2.
SynBioBeta Live Roundtable: Can Humanity Build a Global Antibody Defense Barrier Against Future Pandemics?
Listen to the world’s leading experts on antibody discovery to discuss how we can build a global defensive barrier to find new therapeutic antibodies against the coronavirus and future pathogens.
Webinar: Rapid Discovery of Therapeutic Antibodies for SARS-CoV-2 and Other Viral Pandemics
Watch this on-demand presentation from the 2020 LabRoots Coronavirus Webinar Series to find out how B Cell Antibody Discovery has allowed Berkeley Lights collaborators to discover >500 antibodies to SARS-CoV-2 in a single day.
Datasheet: Opto Plasma B Discovery 2.0 Workflow
Review workflow overview and representative results.
Webinar: Antibody Discovery – Select Better Lead Candidates in Under 1 Week
Learn how we enable lead candidate down-selection in 1 day by performing functional characterization during primary screening. Case studies highlight how our customers are dramatically accelerating development of next-generation antibody therapeutics.
Webinar: Accelerating Antibody Discovery in the Modern Therapeutic Landscape
Learn how antibody discovery is changing in today’s therapeutic space. Case studies presented by Abveris highlight accelerated development of next-generation antibody therapeutics.
Application Note: Rapid Selection of Antibodies Against Membrane Targets using Cell-Binding Assays and the Opto™ Plasma B Discovery
Find out how the Opto Plasma B Discovery workflow simplifies and dramatically reduces the time needed to down-select potential lead candidates, even for difficult membrane proteins.